Greece’s rejection of a bailout package weighed the markets down to a lower close with the Dow losing 46 points to 17,683. Nasdaq fell 17 points to 4,991.

On the upside

The Food and Drug Administration removed a partial clinical hold on Versartis’ (Nasdaq: VSAR) new drug application for VRS-317.

Shares of ConforMIS (Nasdaq: CFMS) continued rising.
 
Aetna approved the use of PDI (Nasdaq: PDII) subsidiary Interpace Diagnostics’ ThyGenX for assessing fine needle aspiration samples.

On the downside

SouFun Holdings (NYSE: SFUN) shareholders adopted its 2015 Stock Incentive Plan.

Allot Communications (Nasdaq: ALLT) warned that second quarter revenue would fall short of expectations.

HSBC analyst Andy Hargreaves affirmed his Buy rating on Weibo (Nasdaq: WB).
 
In the broad market, declining issues outpaced advancers by a margin of more than 5 to 3 on the NYSE and by 7 to 5 on Nasdaq. The broader S&P 500 fell 8 points to 2068. Bitcoin added $2 to $270.